Board initiates buyback activity following period of inactivity, with repurchases executed over the past two trading daysMELBOURNE, Australia and NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced that it has reactivated its previously approved share repurchase program, with the program having been active over the past two trading days. The Company has utilized the buyba ...

Company Joins AASM Foundation Corporate Recognition Program and Sponsors Junior Investigator Research Grant as IHL-42X Advances Toward Potential Oral Treatment for Obstructive Sleep Apnea MELBOURNE, Australia and NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications, today announced it has entered into a Partnership Agreement with the American Academy of Sleep Medicine (AAS ...

MELBOURNE, Australia and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications, today reported that it holds approximately $75 million in cash with no debt, following the completion of its recently announced financing led by dedicated healthcare-focused institutional investors. At current trading levels, Incannex’s market capitalization is approximately $46 million — repres ...

Core Viewpoint - Incannex Healthcare Inc. has regained compliance with Nasdaq's minimum bid price requirement, which allows the company to continue its listing on the Nasdaq Capital Market [1][2][3] Company Compliance - The company received confirmation from Nasdaq that its common stock maintained a closing bid price of $1.00 or greater for eleven consecutive business days from February 27 to March 13, 2026, thus satisfying the listing requirements [2] Financial Position - Incannex Healthcare has approximately $75 million in cash and no debt, positioning the company well to advance its clinical programs [3] Clinical Development - The company is focused on advancing its pipeline, including IHL-42X for obstructive sleep apnea, which has shown statistically significant Phase 2 results, and PSX-001 for generalized anxiety disorder, which has also produced positive clinical outcomes [3][4] Product Pipeline - Incannex is developing combination medicines targeting chronic conditions such as obstructive sleep apnea, rheumatoid arthritis, and generalized anxiety disorder, with three clinical-stage product candidates [4]

Incannex Healthcare Limited (NASDAQ:IXHL) shares are tumbling on Thursday as the company announced a registered direct offering of $10 million. • Incannex Healthcare stock is taking a hit today. What’s weighing on IXHL shares?Seeks Equity Raise Of Up To $23 MillionThe clinical stage biotech company will offer 2 million shares and accompanying warrants to purchase up to 2 million shares at a combined price of $5.If the common warrants are exercised in full for cash, the company would receive up to an additio ...

Core Viewpoint - Incannex Healthcare Inc. has entered into a securities purchase agreement to issue 2,000,000 shares of common stock and accompanying warrants, aiming to raise approximately $10 million, with potential total gross proceeds of up to $23 million if warrants are fully exercised [1][2][3] Financing Details - The financing is expected to close on or about March 13, 2026, subject to customary closing conditions [1] - Each common warrant is exercisable for one share at an exercise price of $6.50, expiring on March 13, 2031 [3] - The gross cash proceeds from the offering are anticipated to be approximately $10 million before deducting fees and expenses [3] Use of Proceeds - Proceeds from the offering are projected to be sufficient to complete the DReAMzz Phase 2 study for IHL-42X, with current cash reserved for Phase 3 development expected to begin in the second half of 2027 [2] - The net proceeds will be allocated for working capital, including research and development expenses, clinical trial expenses, and general corporate purposes [3] Company Overview - Incannex is focused on developing combination medicines targeting chronic conditions such as obstructive sleep apnea, rheumatoid arthritis, and generalized anxiety disorder [7] - The lead clinical program, IHL-42X, is designed to treat obstructive sleep apnea through a combination of dronabinol and acetazolamide [7] - Other clinical candidates include IHL-675A for rheumatoid arthritis and PSX-001 for generalized anxiety disorder, both of which are in various stages of clinical development [7]

Core Insights - Incannex Healthcare has announced an enhanced clinical development strategy for IHL-42X, its lead oral drug candidate for obstructive sleep apnea (OSA), following significant outcomes in its Phase 2 program [1][4][14] Development Strategy - The updated strategy includes a Phase 2 crossover dose-optimization study (DReAMzz) followed by a streamlined Phase 3 clinical program aimed at optimizing efficacy and strengthening the clinical data package [3][12] - The DReAMzz study will evaluate multiple ratios of the active ingredients, dronabinol and acetazolamide, to identify the optimal formulation [6][8] Phase 2 Results - The completed RePOSA Phase 2 trial showed statistically significant improvements in both objective physiological measures and patient-reported outcomes, indicating the therapeutic potential of IHL-42X in OSA [5][7] - In the RePOSA trial, 33.3% of patients in the low-dose group and 41.2% in the high-dose group achieved over 30% reduction in apnea-hypopnea index (AHI), with maximum reductions of 83% and 79% for high and low doses respectively [8] Regulatory Designation - IHL-42X has received Fast Track Designation from the U.S. FDA, allowing for more frequent interactions as the program progresses [2][14] Clinical Advisory Input - The study design for DReAMzz has been developed with input from Incannex's Obstructive Sleep Apnea Clinical Advisory Board and has been reviewed by the FDA [9] Phase 3 Program - Results from the DReAMzz study are expected to facilitate a highly efficient Phase 3 development program, potentially under a single master protocol comprising parallel studies [11][12] - The optimized development design aims to accelerate clinical timelines, reduce costs, and maximize regulatory success probability [12][13] Company Overview - Incannex Healthcare is focused on developing combination medicines targeting chronic conditions, including OSA, and is advancing multiple clinical-stage drug candidates [15]

Incannex Healthcare Inc. (NASDAQ:IXHL) is among the 11 Best Pot Stocks to Buy According to Hedge Funds. Incannex Healthcare Inc. (IXHL) Implements 1-for-30 Reverse Split Effective February 26 On February 25, Incannex Healthcare Inc. (NASDAQ:IXHL) announced that its board of directors approved a 1-for-30 reverse stock split of the company’s common stock. The reverse split had previously been approved by stockholders at a special meeting held on May 27, 2025. The split will take legal effect at 4:01 p.m. E ...

Core Viewpoint - Incannex Healthcare Inc. has announced a 1-for-30 reverse stock split to increase the per share trading price and regain compliance with Nasdaq's minimum bid price requirement [1][3]. Group 1: Reverse Stock Split Details - The reverse stock split will convert every 30 shares of common stock into one share, with no fractional shares issued [2]. - The number of outstanding shares will decrease from approximately 358,329,368 to about 11,944,313 shares, while the total authorized shares will remain unchanged [3]. - The reverse split will take effect at 4:01 p.m. Eastern Time on February 26, 2026, and trading will commence on a split-adjusted basis on February 27, 2026, under a new CUSIP number [1][3]. Group 2: Stockholder Actions - Stockholders holding shares electronically will not need to take any action to receive post-split shares, while those with physical stock certificates will receive instructions for exchanging them [4]. - Stockholders with shares held in "street name" will have their positions automatically adjusted without needing to take action [4]. Group 3: Company Overview - Incannex is focused on developing combination therapies for chronic conditions such as obstructive sleep apnea, rheumatoid arthritis, and generalized anxiety disorder [5]. - The lead clinical program, IHL-42X, is designed to treat obstructive sleep apnea using a combination of dronabinol and acetazolamide [5]. - The company is advancing other clinical-stage drug candidates, including IHL-675A for rheumatoid arthritis and PSX-001 for generalized anxiety disorder [5].

Dallas, Texas--(Newsfile Corp. - February 18, 2026) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL). Incannex continued to build the clinical and patient-reported evidence base for IHL-42X in obstructive sleep apnea (OSA), following full Phase 2 RePOSA data and exit-interview analyses. Both low and high-dose IHL-42X achieved statistically significant reductions in Apnea-Hypopnoea Index (AHI) versus placebo, with maximum ...